The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study
PURPOSE: We evaluated the efficacy of perioperative mitomycin C (MMC) instillation to improve subsequent bacillus Calmette-Guérin (BCG) instillation efficacy in intermediate and high risk patients with non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: From November 2004 to May 2006,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Urologia
2012-08-01
|
| Series: | International Brazilian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382012000400006 |
| _version_ | 1830516848554147840 |
|---|---|
| author | Ömer Gülpinar Ahmet H. Halilioğlu Mehmet İlker Gökçe Çagatay Göğüş Sümer Baltaci |
| author_facet | Ömer Gülpinar Ahmet H. Halilioğlu Mehmet İlker Gökçe Çagatay Göğüş Sümer Baltaci |
| author_sort | Ömer Gülpinar |
| collection | DOAJ |
| description | PURPOSE: We evaluated the efficacy of perioperative mitomycin C (MMC) instillation to improve subsequent bacillus Calmette-Guérin (BCG) instillation efficacy in intermediate and high risk patients with non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: From November 2004 to May 2006, 51 patients with intermediate or high risk NMIBC were enrolled in this prospective randomized trial. In group A, patients were treated with perioperative MMC (40 mg MMC in 40 mL saline was administered within 6 hours of surgery) followed by delayed (at least 15 days from surgery) BCG instillations (once a week for 6 weeks, 5 x 108 colony-forming units in 50 mL saline). Patients in group B were treated with delayed BCG instillations alone. The primary end points were recurrence-free interval and recurrence rate. RESULTS: There were 25 and 26 patients in groups A and B, respectively. Median follow-up was 41.3 months (range 8 to 64) in group A and 40.9 months (range 6 to 68) in group B. Recurrence rate was 36% (9 of 25) and 19.3% (5 of 26) in group A and B, respectively (p = 0.052). Median time to the first recurrence was 8 months in group A and 7 months in group B (p = 0.12). CONCLUSIONS: The present study showed no statistically significant difference in terms of recurrence rate and median time to first recurrence between intermediate or high-risk patients with NMIBC who were treated with early single dose instillation of MMC plus delayed BCG and those who were treated with only BCG. |
| first_indexed | 2024-12-22T03:49:42Z |
| format | Article |
| id | doaj.art-6b8f3a9cd6a44f5783081de7482f8dc9 |
| institution | Directory Open Access Journal |
| issn | 1677-5538 1677-6119 |
| language | English |
| last_indexed | 2024-12-22T03:49:42Z |
| publishDate | 2012-08-01 |
| publisher | Sociedade Brasileira de Urologia |
| record_format | Article |
| series | International Brazilian Journal of Urology |
| spelling | doaj.art-6b8f3a9cd6a44f5783081de7482f8dc92022-12-21T18:40:01ZengSociedade Brasileira de UrologiaInternational Brazilian Journal of Urology1677-55381677-61192012-08-0138447447910.1590/S1677-55382012000400006The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized studyÖmer GülpinarAhmet H. HalilioğluMehmet İlker GökçeÇagatay GöğüşSümer BaltaciPURPOSE: We evaluated the efficacy of perioperative mitomycin C (MMC) instillation to improve subsequent bacillus Calmette-Guérin (BCG) instillation efficacy in intermediate and high risk patients with non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: From November 2004 to May 2006, 51 patients with intermediate or high risk NMIBC were enrolled in this prospective randomized trial. In group A, patients were treated with perioperative MMC (40 mg MMC in 40 mL saline was administered within 6 hours of surgery) followed by delayed (at least 15 days from surgery) BCG instillations (once a week for 6 weeks, 5 x 108 colony-forming units in 50 mL saline). Patients in group B were treated with delayed BCG instillations alone. The primary end points were recurrence-free interval and recurrence rate. RESULTS: There were 25 and 26 patients in groups A and B, respectively. Median follow-up was 41.3 months (range 8 to 64) in group A and 40.9 months (range 6 to 68) in group B. Recurrence rate was 36% (9 of 25) and 19.3% (5 of 26) in group A and B, respectively (p = 0.052). Median time to the first recurrence was 8 months in group A and 7 months in group B (p = 0.12). CONCLUSIONS: The present study showed no statistically significant difference in terms of recurrence rate and median time to first recurrence between intermediate or high-risk patients with NMIBC who were treated with early single dose instillation of MMC plus delayed BCG and those who were treated with only BCG.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382012000400006Urinary Bladder NeoplasmsChemotherapyAdjuvantImmunotherapyBCG Vaccine |
| spellingShingle | Ömer Gülpinar Ahmet H. Halilioğlu Mehmet İlker Gökçe Çagatay Göğüş Sümer Baltaci The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study International Brazilian Journal of Urology Urinary Bladder Neoplasms Chemotherapy Adjuvant Immunotherapy BCG Vaccine |
| title | The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study |
| title_full | The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study |
| title_fullStr | The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study |
| title_full_unstemmed | The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study |
| title_short | The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study |
| title_sort | value of perioperative mitomycin c instillation in improving subsequent bacillus calmette guerin instillation efficacy in intermediate and high risk patients with non muscle invas 305 ve bladder cancer a prospective randomized study |
| topic | Urinary Bladder Neoplasms Chemotherapy Adjuvant Immunotherapy BCG Vaccine |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382012000400006 |
| work_keys_str_mv | AT omergulpinar thevalueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy AT ahmethhalilioamp287lu thevalueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy AT mehmetamp304lkergokce thevalueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy AT cagataygoamp287uamp351 thevalueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy AT sumerbaltaci thevalueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy AT omergulpinar valueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy AT ahmethhalilioamp287lu valueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy AT mehmetamp304lkergokce valueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy AT cagataygoamp287uamp351 valueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy AT sumerbaltaci valueofperioperativemitomycincinstillationinimprovingsubsequentbacilluscalmetteguerininstillationefficacyinintermediateandhighriskpatientswithnonmuscleinvas305vebladdercanceraprospectiverandomizedstudy |